Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Gymnema sylvestre has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Gymnema sylvestre has an excellent potential for the prevention and treatment of metabolic syndrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Letter of consent and release signed by each patient

• Body mass index: 25-34.99 kg/m2

• Body weight without variations above or under 5% during the three months prior to the study

• Diagnostic of metabolic syndrome according to the modified International Diabetes Federation definition: Central obesity (defined as waist circumference ≥ 80 cm in women and ≥ 90 cm in men)

Plus any two of the following four factors:

• Triglycerides: 150-499 mg/dL.

• High density lipoprotein: Woman < 50 mg/dL, man < 40 mg/dL.

• Blood pressure systolic:130-139 mmHg and/or Blood pressure diastolic: 85-89 mmHg

• Fasting glucose: 100-125 mg/dL

Exclusion Criteria:

• Type 1 or 2 diabetes mellitus

• Previous pharmacological treatment for components of metabolic syndrome

• Mental or physical illness interfering with the study

• Thyroid or cardiovascular disease

• Pregnant or suspected pregnant women

• Woman breastfeeding

• Index of body mass: ≥ 35 kg/m2

• Treatments known to affect metabolism of glucose, fats and affecting arterial tension

• Patients with hepatic or renal diseases background

• Patients diagnosed with kidneys disease

• Calcined magnesium intolerance

• Gymnema Sylvestre intolerance